Literature DB >> 9497859

Neuronopathic forms of Gaucher's disease.

A Erikson1, B Bembi, R Schiffmann.   

Abstract

Neuronopathic Gaucher patients may have a wide variety of clinical manifestations and natural history, and can present with a range of degrees of severity of systemic disease and neurological deficit. The brain pathology of these patients has been well described, but the mechanism by which glucocerebrosidase deficiency leads to neuronal dysfunction is not yet understood. The almost 20 different mutations of the glucocerebrosidase gene that have been described in Type 2 and 3 Gaucher patients poorly predict the phenotype of individual patients. Enzyme replacement therapy (ERT), often at high doses, has been shown to reverse most of the systemic manifestations of this disease, but can rarely reverse the neurological deficits. Therefore, other forms of treatment, such as gene therapy or a more efficient and direct enzyme delivery to neurons, are being devised.

Entities:  

Mesh:

Year:  1997        PMID: 9497859     DOI: 10.1016/s0950-3536(97)80035-2

Source DB:  PubMed          Journal:  Baillieres Clin Haematol        ISSN: 0950-3536


  23 in total

Review 1.  Management of neuronopathic Gaucher disease: a European consensus.

Authors:  A Vellodi; B Bembi; T B de Villemeur; T Collin-Histed; A Erikson; E Mengel; A Rolfs; A Tylki-Szymanska
Journal:  J Inherit Metab Dis       Date:  2001-06       Impact factor: 4.982

Review 2.  Inhibition of substrate synthesis as a strategy for glycolipid lysosomal storage disease therapy.

Authors:  F M Platt; M Jeyakumar; U Andersson; D A Priestman; R A Dwek; T D Butters; T M Cox; R H Lachmann; C Hollak; J M Aerts; S Van Weely; M Hrebícek; C Moyses; I Gow; D Elstein; A Zimran
Journal:  J Inherit Metab Dis       Date:  2001-04       Impact factor: 4.982

3.  Glucosidase acid beta gene mutations in Egyptian children with Gaucher disease and relation to disease phenotypes.

Authors:  Zakarya El-Morsy; Mohamed T Khashaba; Othman El-Sayed Soliman; Sohier Yahia; Dina Abd El-Hady
Journal:  World J Pediatr       Date:  2011-06-01       Impact factor: 2.764

Review 4.  Glycosphingolipidoses: beyond the enzymatic defect.

Authors:  Annick Raas-Rothschild; Irene Pankova-Kholmyansky; Yaacov Kacher; Anthony H Futerman
Journal:  Glycoconj J       Date:  2004       Impact factor: 2.916

Review 5.  The clinical management of Type 2 Gaucher disease.

Authors:  Karin Weiss; Ashley Gonzalez; Grisel Lopez; Leah Pedoeim; Catherine Groden; Ellen Sidransky
Journal:  Mol Genet Metab       Date:  2014-11-14       Impact factor: 4.797

6.  Glycolipid analysis of different tissues and cerebrospinal fluid in type II Gaucher disease.

Authors:  R Gornati; B Berra; G Montorfano; C Martini; G Ciana; P Ferrari; M Romano; B Bembi
Journal:  J Inherit Metab Dis       Date:  2002-02       Impact factor: 4.982

7.  Neuronopathic Gaucher disease: demographic and clinical features of 131 patients enrolled in the International Collaborative Gaucher Group Neurological Outcomes Subregistry.

Authors:  Anna Tylki-Szymańska; Ashok Vellodi; Amal El-Beshlawy; J Alexander Cole; Edwin Kolodny
Journal:  J Inherit Metab Dis       Date:  2010-01-19       Impact factor: 4.982

8.  Apparent diffusion coefficient vale of the brain in patients with Gaucher's disease type II and type III.

Authors:  Ahmed Abdel Khalek Abdel Razek; Nahed Abd El-Gaber; Ahmed Abdalla; Abeer Fathy; Ahmed Azab; Ashraf Abdel Rahman
Journal:  Neuroradiology       Date:  2009-07-15       Impact factor: 2.804

9.  Bone events and evolution of biologic markers in Gaucher disease before and during treatment.

Authors:  Jérôme Stirnemann; Nadia Belmatoug; Corine Vincent; Olivier Fain; Bruno Fantin; France Mentré
Journal:  Arthritis Res Ther       Date:  2010-08-09       Impact factor: 5.156

10.  A peptide-linked recombinant glucocerebrosidase for targeted neuronal delivery: Design, production, and assessment.

Authors:  Paul A Gramlich; Wendy Westbroek; Ricardo A Feldman; Ola Awad; Nicholas Mello; Mary P Remington; Ying Sun; Wujuan Zhang; Ellen Sidransky; Michael J Betenbaugh; Paul S Fishman
Journal:  J Biotechnol       Date:  2016-01-18       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.